RHHBF - ImmunoGen's Data For Ovarian Cancer Primes It Up For Several Catalysts Near-Term And In 2022
- ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints.
- A pivotal confirmatory study using mirvetuximab, known as MIRASOL, is expected to have results out by Q3 of 2022. This confirmatory study is a crucial turning point for the company.
- BLA filing of mirvetuximab for patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer expected Q1 of 2022.
- Initial data using IMGN632 with VIDAZA or VENCLEXTA to treat patients with acute myeloid leukemia (AML) to be shown at the 2021 American Society of Hematology (ASH) Annual Meeting in December of 2021.
For further details see:
ImmunoGen's Data For Ovarian Cancer Primes It Up For Several Catalysts Near-Term And In 2022